Written by Jennifer Saueressig, Clinical Quality Manager
After a few early delays, the 2025–2026 fall vaccine rollout is officially underway, with updated COVID-19, flu, and RSV vaccines available nationwide. The CDC Director has adopted the latest Advisory Committee on Immunization Practices (ACIP) recommendations, reaffirming that vaccination remains the best defense against severe respiratory illness.
The CDC now recommends COVID-19 vaccination for everyone six months and older through a shared clinical decision-making approach, reinforcing the patient-centered model already practiced in health centers. All available vaccines, Moderna, Pfizer, and Novavax, are updated formulations. New this year is Moderna’s mNexspike, a lower-dose option for patients aged 12 and older. National groups, including the AAP and ACOG, continue to recommend vaccination for young children, pregnant individuals, and adults with chronic conditions to prevent serious illness and long COVID.
North Dakota has received an initial, limited supply of updated COVID-19 vaccine doses. Allocations are being distributed based on earlier prebook submissions, with weekly shipments expected through the next month. Health centers will have an opportunity to review their allocations before orders are finalized. Medicaid will continue to reimburse for the cost and administration of COVID-19 vaccines for children enrolled in Medicaid until the VFC vaccine supply is distributed statewide. The South Dakota Department of Health has also opened ordering for VFC and VFA providers to begin receiving doses for eligible populations. For guidance on immunization coverage at health centers, see the Medicaid FQHC provider manuals for North Dakota and South Dakota. The flu vaccine continues to be recommended for everyone six months and older, with early data showing a 50% effectiveness rate against hospitalization. Flublok® has been approved for ages nine and older, and thimerosal-free options are preferred for children, pregnant individuals, and adults. RSV vaccination recommendations now include monoclonal antibody protection for infants entering their first RSV season and single-dose vaccines for adults 50–59 at risk, and all adults 75 and older.
This year’s immunization updates underscore the continued need for proactive outreach, strong care coordination, and clear communication with patients. Vaccines remain the best defense against severe respiratory disease and can safely be administered together during the same visit.
For more background on this season’s vaccine science and practical patient guidance, providers can reference Katelyn Jetelina’s 2025 Fall Vaccine Guide and the Common Health Coalition’s SCDM Clinical Explainer, which translate complex updates into accessible, evidence-based talking points for clinical teams and patient education.
Additional Resources:
